Articles

Results 1 to 5 of 18
Most popular |Most recent


Litigation on Amgen’s Biosimilar to Avastin Settles on Heels of Amgen Procedural Victory at Federal Circuit

USA - July 13 2020 We have previously covered various aspects of a legal battle between Genentech and Amgen regarding Amgen’s efforts to market Mvasi, a biosimilar to…

Uptick in PTAB Motions to Amend Demonstrate Increasing Importance of this Strategy

USA - March 11 2020 To put the numbers in context, the USPTO publishes studies on the outcomes of motions to amend in AIA trials. The studies are available here. The…

2019 Ends and 2020 Begins with a Flurry of Biosimilar Activity in East Asian Markets

China - February 24 2020 A white paper released in 2019 by The Biosimilars Forum and Medicines for Europe shows the United States and Europe accounting for more than a…

Presence of Harm Central to Real Party-in-Interest Issues in PTAB Precedential Decisions

USA - April 24 2019 On April 16, 2019, the Patent Trial and Appeal Board (“the PTAB” or “the Board”) designated three orders as precedential related to the issue of the…

2 Door Makers And The Gutting Of Pre-Merger Clearance

USA - August 22 2018 The century-old Clayton Act makes unlawful mergers or acquisitions that may have of the effect of substantially lessening competition. Remedies for…

Derek F. Dahlgren.